GIMAP8

Summary

GIMAP8 (GTPase, IMAP family member 8, HGNC:21792) is a protein-coding gene on chromosome 7q36.1, encoding GTPase IMAP family member 8 (Q8ND71). Exerts an anti-apoptotic effect in the immune system and is involved in responses to infections.

This gene encodes a protein belonging to the GTP-binding superfamily and to the immuno-associated nucleotide (IAN) subfamily of nucleotide-binding proteins. In humans, the IAN subfamily genes are located in a cluster at 7q36.1.

Source: NCBI Gene 155038 — RefSeq curated summary.

At a glance

• Clinical variants (ClinVar): 116 total — 1 pathogenic
• Phenotypes (HPO): 1
• MANE Select transcript: NM_175571

Identifiers

Gene identifiers

Field	Value
HGNC ID	HGNC:21792
Approved symbol	GIMAP8
Name	GTPase, IMAP family member 8
Location	7q36.1
Locus type	gene with protein product
Status	Approved
Aliases	DKFZp667I133, hIAN6, IAN9
Ensembl gene	ENSG00000171115
Ensembl biotype	protein_coding
OMIM	616962
Entrez	155038

Gene structure

Transcript identifiers

Ensembl transcripts: 10 — 10 protein_coding

ENST00000307271, ENST00000901633, ENST00000901634, ENST00000901635, ENST00000901636, ENST00000901637, ENST00000901638, ENST00000954718, ENST00000954719, ENST00000954720

RefSeq mRNA: 1 — MANE Select: NM_175571 NM_175571

CCDS: CCDS34777

Canonical transcript exons

ENST00000307271 — 5 exons

Exon	Start	End
ENSE00001141785	150466671	150467334
ENSE00001255645	150474012	150474638
ENSE00001255660	150470829	150470874
ENSE00001255678	150477092	150479393
ENSE00001255685	150450630	150451175

Expression profiles

Bgee: expression breadth ubiquitous, 241 present calls, max score 96.02.

FANTOM5 (CAGE): breadth broad, TPM avg 4.7992 / max 116.5673, expressed in 516 samples.

FANTOM5 promoters (9 alternative TSS)

Promoter ID	TPM avg	Samples expressed
81942	0.9078	343
81944	0.8283	359
81945	0.7772	320
81947	0.6855	265
81948	0.6652	183
81950	0.3318	128
81943	0.2794	154
81946	0.2730	186
81951	0.0509	18

Top tissues by expression

254 total, by Bgee expression score (0-100, higher = more expressed):

Tissue	Anatomy ID	Expression score	Quality
tendon of biceps brachii	UBERON:0008188	96.02	gold quality
left ventricle myocardium	UBERON:0006566	95.29	gold quality
cardiac muscle of right atrium	UBERON:0003379	94.96	gold quality
superficial temporal artery	UBERON:0001614	94.12	gold quality
leukocyte	CL:0000738	93.20	gold quality
right lung	UBERON:0002167	93.18	gold quality
monocyte	CL:0000576	93.03	gold quality
visceral pleura	UBERON:0002401	92.75	gold quality
granulocyte	CL:0000094	92.28	gold quality
lower lobe of lung	UBERON:0008949	92.25	gold quality
myocardium	UBERON:0002349	91.81	gold quality
parietal pleura	UBERON:0002400	91.67	gold quality
layer of synovial tissue	UBERON:0007616	91.63	gold quality
urethra	UBERON:0000057	91.34	gold quality
heart right ventricle	UBERON:0002080	91.30	gold quality
spleen	UBERON:0002106	90.31	gold quality
lung	UBERON:0002048	89.49	gold quality
lymph node	UBERON:0000029	88.81	gold quality
upper lobe of lung	UBERON:0008948	88.51	gold quality
vermiform appendix	UBERON:0001154	88.41	gold quality
blood	UBERON:0000178	88.21	gold quality
upper lobe of left lung	UBERON:0008952	88.19	gold quality
pericardium	UBERON:0002407	87.93	gold quality
caecum	UBERON:0001153	87.30	gold quality
apex of heart	UBERON:0002098	87.15	gold quality
tendon	UBERON:0000043	86.98	gold quality
subcutaneous adipose tissue	UBERON:0002190	86.85	gold quality
synovial joint	UBERON:0002217	86.75	gold quality
adipose tissue	UBERON:0001013	86.17	gold quality
calcaneal tendon	UBERON:0003701	85.85	gold quality

Single-cell (SCXA)

Detected in 2 experiment(s), a significant marker in 1.

Experiment	Marker?	Max mean expression
E-ANND-3	yes	8.84
E-MTAB-8205	no	181.18

Regulation

Is transcription factor: no

miRNA regulators (miRDB)

61 targeting GIMAP8, top 30 by miRDB confidence (max_score; target_count = how many genes the miRNA targets in total — lower means more specific):

miRNA	Max score	Avg score	miRNA target_count
HSA-MIR-4795-3P	100.00	74.62	4024
HSA-MIR-6873-3P	100.00	71.42	2626
HSA-MIR-7110-3P	100.00	73.18	2486
HSA-MIR-126-5P	100.00	72.71	3180
HSA-MIR-4682	100.00	68.89	1258
HSA-MIR-520G-5P	99.99	66.76	658
HSA-MIR-205-3P	99.92	69.92	3165
HSA-MIR-3941	99.86	70.54	2735
HSA-MIR-3180-5P	99.82	69.12	2422
HSA-MIR-6739-5P	99.80	67.87	2806
HSA-MIR-4694-3P	99.79	69.53	2640
HSA-MIR-8076	99.78	68.52	1170
HSA-MIR-6733-5P	99.74	67.94	2759
HSA-MIR-4428	99.73	66.41	1733
HSA-MIR-1283	99.69	72.42	3009
HSA-MIR-7-5P	99.67	70.53	1809
HSA-MIR-378A-5P	99.65	66.33	1311
HSA-MIR-5197-5P	99.64	69.08	1494
HSA-MIR-12122	99.56	69.33	1672
HSA-MIR-3153	99.55	67.59	2337
HSA-MIR-409-3P	99.50	66.33	1192
HSA-MIR-4441	99.49	66.56	3216
HSA-MIR-4735-5P	99.43	68.49	1780
HSA-MIR-5683	99.36	68.59	2083
HSA-MIR-4652-3P	99.33	70.02	2742
HSA-MIR-1912-3P	99.32	67.40	936
HSA-MIR-580-5P	99.28	70.94	1776
HSA-MIR-499A-3P	99.18	69.20	1392
HSA-MIR-499B-3P	99.18	69.27	1391
HSA-MIR-3125	99.14	68.49	2269

Cross-species orthologs

2 orthologs

Organism	Symbol	Gene ID
mus_musculus	Gimap8	ENSMUSG00000064262
rattus_norvegicus	Gimap8	ENSRNOG00000020169

Paralogs (7): GIMAP2 (ENSG00000106560), GIMAP6 (ENSG00000133561), GIMAP4 (ENSG00000133574), GIMAP7 (ENSG00000179144), GIMAP5 (ENSG00000196329), GIMAP1 (ENSG00000213203), GIMD1 (ENSG00000250298)

Protein

Protein identifiers

GTPase IMAP family member 8 — Q8ND71 (reviewed: Q8ND71)

Alternative names: Immune-associated nucleotide-binding protein 9, Protein IanT

All UniProt accessions (1): Q8ND71

UniProt curated annotations — full annotation on UniProt →

Function. Exerts an anti-apoptotic effect in the immune system and is involved in responses to infections.

Subcellular location. Endoplasmic reticulum. Golgi apparatus. Mitochondrion. Cytoplasm. Cytosol.

Tissue specificity. Expressed in the spleen, intestine, liver, and colon, as well as in lung, placenta, kidney, muscle, and heart. Extremely low expression, if any, in brain, in thymus, bone marrow, and blood leukocytes. Detected in T-cells.

Similarity. Belongs to the TRAFAC class TrmE-Era-EngA-EngB-Septin-like GTPase superfamily. AIG1/Toc34/Toc159-like paraseptin GTPase family. IAN subfamily.

RefSeq proteins (1): NP_783161* (*=MANE)

Domains & families (InterPro)

ID	Name	Type
IPR006703	G_AIG1	Domain
IPR027417	P-loop_NTPase	Homologous_superfamily
IPR045058	GIMA/IAN/Toc	Family

Pfam: PF04548

UniProt features (19 total): region of interest 6, binding site 4, domain 3, coiled-coil region 2, compositionally biased region 2, chain 1, sequence variant 1

Structure

Experimental structures (PDB)

0 structures.

Predicted structure (AlphaFold)

Model	pLDDT	Fraction very-high
AF-Q8ND71-F1	81.90	0.43

Functional residue map

Curated UniProt residues grouped by drug-discovery relevance — catalytic, ligand-binding, modification, and mutation-validated positions. Source: UniProtKB sequence features.

Ligand- & substrate-binding residues (4): 17–25; 38; 135–137; 170

Function

Pathways and Gene Ontology

Reactome pathways

0 pathways

MSigDB gene sets: 116 (showing top): GOBP_REGULATION_OF_LEUKOCYTE_APOPTOTIC_PROCESS, GOBP_REGULATION_OF_LYMPHOCYTE_APOPTOTIC_PROCESS, LEE_NAIVE_T_LYMPHOCYTE, GOBP_REGULATION_OF_T_CELL_APOPTOTIC_PROCESS, GOBP_LEUKOCYTE_APOPTOTIC_PROCESS, CUI_TCF21_TARGETS_2_DN, RIGGI_EWING_SARCOMA_PROGENITOR_UP, GOBP_LYMPHOCYTE_APOPTOTIC_PROCESS, GOBP_T_CELL_APOPTOTIC_PROCESS, GOMF_GTPASE_ACTIVITY, GOMF_HYDROLASE_ACTIVITY_ACTING_ON_ACID_ANHYDRIDES, HATADA_METHYLATED_IN_LUNG_CANCER_UP, BOSCO_TH1_CYTOTOXIC_MODULE, GARGALOVIC_RESPONSE_TO_OXIDIZED_PHOSPHOLIPIDS_PINK_DN, GSE10240_CTRL_VS_IL22_STIM_PRIMARY_BRONCHIAL_EPITHELIAL_CELLS_UP

GO Biological Process (1): regulation of T cell apoptotic process (GO:0070232)

GO Molecular Function (3): GTPase activity (GO:0003924), GTP binding (GO:0005525), nucleotide binding (GO:0000166)

GO Cellular Component (5): mitochondrion (GO:0005739), endoplasmic reticulum (GO:0005783), Golgi apparatus (GO:0005794), cytosol (GO:0005829), cytoplasm (GO:0005737)

GO top-level categories

Rollup of top GO terms by namespace:

Category	Terms
cytoplasm	4
intracellular membrane-bounded organelle	3
endomembrane system	2
cellular anatomical structure	2
regulation of lymphocyte apoptotic process	1
T cell apoptotic process	1
ribonucleoside triphosphate phosphatase activity	1
guanyl ribonucleotide binding	1
purine ribonucleoside triphosphate binding	1
nucleoside phosphate binding	1
heterocyclic compound binding	1
intracellular anatomical structure	1

Protein interactions and networks

STRING

1694 interactions, top by confidence (×1000):

Protein A	Protein B	Partner UniProt	Score
GIMAP8	ZNF775	Q96BV0	507
GIMAP8	GIMAP7	Q8NHV1	469
GIMAP8	GIMAP6	Q6P9H5	467
GIMAP8	CARNS1	A5YM72	460
GIMAP8	GIMAP1	Q8WWP7	447
GIMAP8	TMEM102	Q8N9M5	434
GIMAP8	DNAJC14	Q6Y2X3	428
GIMAP8	PADI2	Q9Y2J8	426
GIMAP8	TMEM176B	Q3YBM2	409
GIMAP8	ELOVL4	Q9GZR5	407
GIMAP8	ZNF385C	Q66K41	404
GIMAP8	GIMAP4	Q9NUV9	399
GIMAP8	OR52K1	Q8NGK4	396
GIMAP8	PARP14	Q460N5	390
GIMAP8	TMCO4	Q5TGY1	388
GIMAP8	ASTN1	O14525	388

IntAct

11 interactions, top by confidence:

A	B	Type	Score
GIMAP8	LRRK2	psi-mi:“MI:0407”(direct interaction)	0.440
GIMAP8	EIF3A	psi-mi:“MI:0915”(physical association)	0.400
PB2	SEC15L3	psi-mi:“MI:0914”(association)	0.350
PB2		psi-mi:“MI:0914”(association)	0.350
CTNNA3	ARVCF	psi-mi:“MI:0914”(association)	0.350
GIMAP8	OAS2	psi-mi:“MI:0914”(association)	0.350
GIMAP8	SRP72	psi-mi:“MI:0914”(association)	0.350
CDH5	ESYT2	psi-mi:“MI:2364”(proximity)	0.270
GIMAP8		psi-mi:“MI:0915”(physical association)	0.000

BioGRID (33): GIMAP8 (Affinity Capture-MS), OAS2 (Affinity Capture-MS), SRP68 (Affinity Capture-MS), SRP54 (Affinity Capture-MS), GIMAP8 (Affinity Capture-MS), POLR3E (Affinity Capture-MS), GIMAP8 (Affinity Capture-MS), GIMAP8 (Co-fractionation), GIMAP8 (Co-fractionation), GIMAP8 (Co-fractionation), GIMAP8 (Co-fractionation), GIMAP8 (Co-fractionation), AK3 (Co-fractionation), COA4 (Co-fractionation), TXN2 (Co-fractionation)

ESM2 similar proteins: A1E2I4, A7VK00, B0BMZ3, E9PW74, F4HT21, G3MZQ6, G3X987, O81025, P09922, P0DJR0, P18588, P18589, P18590, P20591, P27473, P32455, P33237, P54120, P79135, Q28379, Q4ADG6, Q4ADG7, Q4ADG8, Q4KLG2, Q5D1D6, Q5R5G3, Q5RBE1, Q75N62, Q8BV66, Q8K3K9, Q8N8V2, Q8ND71, Q8NHV1, Q8TCB0, Q99JY3, Q9BDB7, Q9C8U2, Q9C8U5, Q9C8U6, Q9C8U7

Diamond homologs: A5PKB7, F4HT21, G3X987, O23680, O81025, P54120, P70224, Q41009, Q4KLG2, Q5FVN6, Q6P9H5, Q75N62, Q8BWF2, Q8K349, Q8K3K9, Q8K3L6, Q8ND71, Q8NHV1, Q8WWP7, Q96F15, Q99JY3, Q99MI6, Q9C8U2, Q9C8V0, Q9C8V2, Q9NUV9, Q9T0F2, Q9T0F3, Q9T0F4, Q9UG22, E9PW74, Q9C8U5, Q9C8U6, Q9C8U7, Q9C8U8, Q9LVT3, O81283, C0HJV2, G3MZQ6, O81865

SIGNOR signaling

0 interactions.

Disease & clinical

Clinical variants and AI predictions

ClinVar

116 variants total. Per-class counts are floors (≥ shown; pagination cap):

Classification	Count (floor)
Pathogenic	1
Likely pathogenic	0
Uncertain significance	98
Likely benign	13
Benign	0

Top pathogenic / likely-pathogenic (1)

Variant ID	HGVS	Classification
2583057	GRCh37/hg19 7q34-36.1(chr7:140154317-152551638)x1	Pathogenic

SpliceAI

963 predictions. Top by Δscore:

Variant	Effect	Δscore
7:150467330:TTCAA:T	donor_loss	1.0000
7:150467335:G:GG	donor_gain	1.0000
7:150467335:GTAA:G	donor_loss	1.0000
7:150467336:T:A	donor_loss	1.0000
7:150470873:GG:G	donor_gain	1.0000
7:150470874:GG:G	donor_gain	1.0000
7:150470874:GGT:G	donor_loss	1.0000
7:150470875:G:GC	donor_loss	1.0000
7:150470876:T:A	donor_loss	1.0000
7:150451069:G:GT	donor_gain	0.9900
7:150454477:GGC:G	donor_gain	0.9900
7:150466669:A:AG	acceptor_gain	0.9900
7:150466670:G:GG	acceptor_gain	0.9900
7:150466778:G:GT	donor_gain	0.9900
7:150466779:A:T	donor_gain	0.9900
7:150466802:TGTTC:T	donor_gain	0.9900
7:150466810:TCC:T	donor_gain	0.9900
7:150466816:T:G	donor_gain	0.9900
7:150470827:AG:A	acceptor_gain	0.9900
7:150470828:GG:G	acceptor_gain	0.9900
7:150470875:G:GG	donor_gain	0.9900
7:150477086:T:TA	acceptor_gain	0.9900
7:150477087:GACAG:G	acceptor_loss	0.9900
7:150477089:CAGA:C	acceptor_loss	0.9900
7:150477090:A:AG	acceptor_gain	0.9900
7:150477090:A:C	acceptor_loss	0.9900
7:150477091:G:GC	acceptor_loss	0.9900
7:150477091:G:GG	acceptor_gain	0.9900
7:150477091:GA:G	acceptor_gain	0.9900
7:150477091:GAA:G	acceptor_gain	0.9900

AlphaMissense

4414 scored. Top likely-pathogenic:

Variant	Protein change	am_pathogenicity
7:150474108:A:T	K260I	0.977
7:150477172:T:C	F464L	0.971
7:150477174:C:A	F464L	0.971
7:150477174:C:G	F464L	0.971
7:150474110:A:C	S261R	0.965
7:150474112:T:A	S261R	0.965
7:150474112:T:G	S261R	0.965
7:150474146:T:C	F273L	0.962
7:150474148:T:A	F273L	0.962
7:150474148:T:G	F273L	0.962
7:150474109:A:C	K260N	0.961
7:150474109:A:T	K260N	0.961
7:150477254:T:A	V491D	0.955
7:150477136:A:C	S452R	0.954
7:150477138:T:A	S452R	0.954
7:150477138:T:G	S452R	0.954
7:150474108:A:C	K260T	0.952
7:150474078:T:A	V250D	0.946
7:150474090:G:T	G254V	0.937
7:150474107:A:G	K260E	0.936
7:150474107:A:C	K260Q	0.931
7:150477368:T:A	V529D	0.930
7:150477583:T:C	F601L	0.928
7:150477585:T:A	F601L	0.928
7:150477585:T:G	F601L	0.928
7:150467059:T:C	F121L	0.927
7:150467061:T:A	F121L	0.927
7:150467061:T:G	F121L	0.927
7:150466804:T:C	F36L	0.924
7:150466806:C:A	F36L	0.924

dbSNP variants (sampled 300 via entrez): RS1000037693 (7:150449134 T>G), RS1000119585 (7:150453510 G>A,C), RS1000221743 (7:150475116 A>G), RS1000255791 (7:150453751 T>G), RS1000266753 (7:150468620 A>G), RS1000322645 (7:150468389 T>G), RS1000408876 (7:150449387 A>C), RS1000486799 (7:150461739 T>C), RS1000573776 (7:150475460 A>G), RS1000590094 (7:150452367 G>A), RS1000749831 (7:150459822 C>A), RS1000852389 (7:150462118 A>T), RS1001087296 (7:150472376 A>G), RS1001180828 (7:150463829 T>C), RS1001223754 (7:150460358 A>G)

Disease associations

OMIM: gene MIM:616962 | disease phenotypes: MIM:209850

GenCC curated gene-disease

Mondo (1): autism (MONDO:0005260)

Orphanet (0):

HPO phenotypes

1 total (1 of 1 shown, HPO-id order):

HPO	Term
HP:0000717	Autism

GWAS associations

0 associations (top):

MeSH disease descriptors (1)

Descriptor	Name	Tree numbers
D001321	Autistic Disorder	F03.625.164.113.500

Drugs & pharmacology

Drug and pharmacology data

Is drug target: no

PharmGKB: 1 entry (VIP=true, CPIC=false)

CTD chemical–gene interactions

20 total (human), top 20 by PubMed support.

Chemical	Actions (top 5)	PubMed papers
Benzo(a)pyrene	affects methylation, increases expression, increases methylation	3
Aflatoxin B1	increases expression, decreases methylation	2
GSK-J4	decreases expression	1
triphenyl phosphate	affects expression	1
sodium arsenite	increases expression	1
S-(1,2-dichlorovinyl)cysteine	decreases reaction, increases expression	1
di-n-butylphosphoric acid	affects expression	1
picoxystrobin	decreases expression	1
Acetaminophen	increases expression	1
Air Pollutants, Occupational	decreases expression	1
Calcitriol	increases expression	1
Doxorubicin	decreases expression	1
Ethyl Methanesulfonate	decreases expression	1
Lipopolysaccharides	increases expression, decreases reaction	1
Methyl Methanesulfonate	decreases expression	1
Nickel	decreases expression	1
Tobacco Smoke Pollution	increases expression	1
Triclosan	decreases expression	1
Valproic Acid	increases methylation	1
8-Bromo Cyclic Adenosine Monophosphate	decreases expression	1

Clinical trials (associated diseases)

300 trials via MONDO — disease-level, not drug-specific.

Trial	Phase	Status	Title
NCT00211796	PHASE4	COMPLETED	Divalproex Sodium ER in Adult Autism
NCT00391261	PHASE4	COMPLETED	An Open-label Trial of Metformin for Weight Control of Pediatric Patients on Antipsychotic Medications.
NCT00409747	PHASE4	COMPLETED	Minocycline to Treat Childhood Regressive Autism
NCT00576732	PHASE4	COMPLETED	A Study of the Effectiveness and Safety of Two Doses of Risperidone in the Treatment of Children and Adolescents With Autistic Disorder
NCT00844753	PHASE4	COMPLETED	Atomoxetine, Placebo and Parent Management Training in Autism
NCT01028820	PHASE4	COMPLETED	FMRI Brain Activation of Aripiprazole Treatment in Autism Spectrum Disorders
NCT01098383	PHASE4	UNKNOWN	Treatment With Acetyl-Choline Esterase Inhibitors in Children With Autism Spectrum Disorders
NCT01333865	PHASE4	COMPLETED	A Study of Memantine Hydrochloride (Namenda®) for Cognitive and Behavioral Impairment in Adults With Autism Spectrum Disorders
NCT01337700	PHASE4	COMPLETED	Milnacipran in Autism and the Functional Locus Coeruleus and Noradrenergic Model of Autism
NCT01695200	PHASE4	COMPLETED	Omega-3 Fatty Acids in Autism Spectrum Disorders
NCT02069977	PHASE4	UNKNOWN	Study to Evaluate the Efficacy and Safety of Aripiprazole
NCT02096952	PHASE4	COMPLETED	Methylphenidate ER Liquid Formulation in Adults With ASD and ADHD
NCT02199925	PHASE4	UNKNOWN	An Open-Label Study to Evaluate the Efficacy of High-Dose Gammaplex in Children on the Autism Spectrum
NCT02235467	PHASE4	COMPLETED	Multisite Study: Parental Training Using Video Modelling to Develop Social Skills in Children With Autism
NCT02255565	PHASE4	COMPLETED	Dose Response Effects of Quillivant XR in Children With ADHD and Autism: A Pilot Study
NCT02940574	PHASE4	COMPLETED	Neural and Behavioral Effects of Oxytocin in Autism Spectrum Disorders
NCT03333629	PHASE4	COMPLETED	Promoting Positive Outcomes for Individuals With ASD: Linking Early Detection, Treatment, and Long-term Outcomes
NCT03337646	PHASE4	COMPLETED	Evaluation of the Effect and Safety of Lisdexamfetamine in Children Aged 6-12 With ADHD and Autism
NCT03538431	PHASE4	COMPLETED	Improving Driving in Young People With Autism Spectrum Disorders
NCT03757585	PHASE4	COMPLETED	Natural Treatments for the Management of Emotional Dysregulation in Youth With Non-verbal Learning Disability (NVLD) and/or Autism Spectrum Disorders (ASD)
NCT04903353	PHASE4	COMPLETED	Pragmatic Trial Comparing Weight Gain in Children With Autism Taking Risperidone Versus Aripiprazole
NCT05063656	PHASE4	COMPLETED	Biomarker-Driven Pharmacological Treatment of Adolescents With Autism Spectrum Disorder With Gabapentin
NCT05146245	PHASE4	UNKNOWN	Safety and Pharmacokinetics of Antipsychotics in Children 2: Studying TDM in an RCT
NCT05916339	PHASE4	RECRUITING	AWARE: Management of ADHD in Autism Spectrum Disorder
NCT05954052	PHASE4	TERMINATED	A Study of Glutathione in Children With Autism Spectrum Disorder
NCT06853665	PHASE4	RECRUITING	The TEAM Study - Treatment Efficacy for Autism/Attention Using Mixed Amphetamine
NCT07054697	PHASE4	COMPLETED	Pilot-RCT With Individualized Homeopathic Treatment in the Children With Autism Spectrum Disorder
NCT07161804	PHASE4	COMPLETED	Pilot RCT Using Homeopathic Medicines in ASD
NCT07439042	PHASE4	NOT_YET_RECRUITING	Buspirone for Anxiety in Autistic Youth
NCT00036231	PHASE3	TERMINATED	Synthetic Human Secretin in Children With Autism and Gastrointestinal Dysfunction
NCT00036244	PHASE3	COMPLETED	Synthetic Human Secretin in Children With Autism
NCT00065884	PHASE3	UNKNOWN	Valproate Response in Aggressive Autistic Adolescents
NCT00065962	PHASE3	COMPLETED	Secretin for the Treatment of Autism
NCT00252603	PHASE3	COMPLETED	Galantamine Versus Placebo in Childhood Autism
NCT00346736	PHASE3	COMPLETED	Use of Acupuncture In Children With Autistic Spectrum Disorder
NCT00352248	PHASE3	COMPLETED	Randomized Controlled Trial of Acupuncture Versus Sham Acupuncture in Autistic Spectrum Disorder
NCT00352352	PHASE3	COMPLETED	Use of Acupuncture In Children With Autistic Spectrum Disorder
NCT00355329	PHASE3	COMPLETED	Randomized Control Trial of Using Tongue Acupuncture in Autistic Spectrum Disorder Using PET Scan for Clinical Correlation
NCT00498173	PHASE3	COMPLETED	Effectiveness of Atomoxetine in Treating ADHD Symptoms in Children and Adolescents With Autism
NCT00541346	PHASE3	COMPLETED	A Pilot Study of Daytrana TM in Children With Autism Co-Morbid for Attention Deficit Hyperactivity Disorder (ADHD) Symptoms